Amgen readies pivotal MariTide trials; Novo offers discounted Wegovy

Phase 3 studies for Amgen’s closely watched obesity drug were posted on a federal database. Elsewhere, the FDA cleared for testing a first-of-its-kind base editing therapy for Duchenne.

By BioPharma Dive staff • March 6, 2025

Bayer braces for ‘difficult’ year before turnaround pays dividends

CEO Bill Anderson warned investors that profits will decline in 2025 before the company’s ongoing shake-up leads to an “improved trajectory” next year. 

By Kristin Jensen • March 5, 2025

Explore the Trendline➔

Top 5 stories from BioPharma Dive

Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.

By BioPharma Dive staff

Trump administration policies could create headwinds across healthcare: Fitch

The administration’s initiatives could negatively impact the credit ratings of an array of companies, among them large drugmakers, Fitch said. 

By Susanna Vogel • March 4, 2025

Neumora bids farewell to R&D head; Biohaven’s ‘one step forward, one step back’ data

Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Atara is cutting half of its staff after shelving two cell therapy programs.

By BioPharma Dive staff • March 4, 2025

Leqembi, after delay, gets back on track toward EU approval

European regulators “reaffirmed” a positive view of Eisai and Biogen’s Alzheimer’s drug after conducting a new safety review.

By Jonathan Gardner • Feb. 28, 2025

Praxis hits trial setback; Bristol Myers lays off staff in New Jersey

The brain drug developer is continuing a trial despite a recommendation it be stopped for futility. Elsewhere, Eli Lilly struck a molecular glue deal and Zevra sold a priority review voucher.

By BioPharma Dive staff • Feb. 28, 2025

Lilly CEO wields manufacturing plans to push pharma-friendly policies

While announcing billions of dollars in new U.S. investments, David Ricks called for an extension of 2017 tax cuts and changes to Medicare's drug negotiation program.

By Ned Pagliarulo • Feb. 26, 2025

AstraZeneca’s next breast cancer drug; Madrigal’s accelerating MASH launch

The British drugmaker claimed success in a first-line breast cancer study. Elsewhere, Rezdiffra sales continued to grow and a cancer biotech cut staff.

By BioPharma Dive staff • Feb. 26, 2025

Lilly expands US manufacturing build-out with $50B target

The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry to reshore drug production.

By Ned Pagliarulo • Feb. 26, 2025

Summit partners with Pfizer to study bispecific, ADC combinations

The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially landscape-changing combinations.”

By Jonathan Gardner • Feb. 24, 2025

Pfizer names Patrizia Cavazzoni, former top FDA official, as chief medical officer

Cavazzoni stepped down from her role as head of the FDA’s main drug review office in mid-January. She will succeed Aida Habtezion.

By Ned Pagliarulo • Feb. 24, 2025

Ozempic, Wegovy shortage resolved; Pfizer CEO is PhRMA’s new chair

The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a competing bid for Acelyrin and Intra-Cellular sales rose.

By BioPharma Dive staff • Updated Feb. 24, 2025

Pfizer stops selling hemophilia gene therapy, citing weak demand

Pfizer’s decision to halt further marketing of Beqvez is further sign of the sparse patient interest in gene therapies for the bleeding condition.

By Ned Pagliarulo • Feb. 21, 2025

AstraZeneca deepens China presence with FibroGen deal

The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foothold in China while the company works through government investigations into its business practices there. 

By Kristin Jensen • Feb. 20, 2025

Sanofi reaches consumer health deal; Supernus antidepressant fails study

The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Ultragenyx secured a PDUFA date for its Sanfilippo gene therapy.

By BioPharma Dive staff • Feb. 19, 2025

FTC retains stricter merger guidelines under Trump

Agency chair Andrew Ferguson sent a memo to staff on Tuesday clarifying that Biden-era guidelines will remain in place — for now.

By Rebecca Pifer Parduhn • Feb. 19, 2025

GSK’s 5-in-1 meningococcal shot wins FDA approval

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through 25 years old.

By Delilah Alvarado • Updated Feb. 18, 2025

Neumora shakes up its C-suite; Biogen cuts early-stage pipeline

Henry Gosebruch, Neumora’s CEO since 2023, will depart. Elsewhere, Biogen dropped two antisense drugs in a pipeline cull and Voyager hit a setback for its ALS gene therapy.

By BioPharma Dive staff • Feb. 13, 2025

RFK Jr. confirmed by Senate as health secretary

All but one Senate Republican voted for Kennedy, a controversial vaccine critic whose embrace of the “Make America Healthy Again” movement helped him win one of the most powerful jobs in Washington.

By Delilah Alvarado , Emily Olsen • Feb. 13, 2025

New study offers hints of GLP-1 drugs’ potential in curbing alcohol cravings

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed to establish a conclusive benefit.

By Jonathan Gardner • Feb. 12, 2025

Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK

The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority review on a key drug and Third Harmonic restructured.

By BioPharma Dive staff • Feb. 11, 2025

Novartis pays $925M to reel in a startup it helped launch

The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed to the Blackstone-backed startup six years ago.

By Ben Fidler • Feb. 11, 2025

The role of diagnostics in advancing antibody-drug conjugates

Antibody-drug conjugates (ADCs) are revolutionizing oncology, but success requires precision diagnostics.

By Thomas P. Salvin, MD, MBA, Chief Clinical Officer, Molecular Diagnostics, Quest Diagnostics • Feb. 10, 2025

Bain buys Mitsubishi pharma unit; Bausch + Lomb deal talks come up empty

The investment firm is acquiring Mitsubishi Tanabe Pharma in a deal valued at $3.3 billion. Elsewhere, Bausch + Lomb hasn’t yet found a suitor and a pair of biotechs cut staff.

By BioPharma Dive staff • Feb. 7, 2025

Bristol Myers, bracing for key patent losses, deepens cost-cutting plan

The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies across multiple areas of the business,” its CFO told analysts on a conference call. 

By Delilah Alvarado • Feb. 6, 2025